Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs

ASCO Education Podcast

0:00
06:59
10
10

Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs

ASCO Education Podcast

Dr. Jonathan Strosberg, section chief of the Neuroendocrine Tumor Division of the Moffitt Cancer Center, discusses the recent FDA approval of Lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Episodes
Date
Duration
Recommended episodes :

Cancer Topics – Medicinal Cannabis

ASCO Education Podcast

Oncology, Etc. - In Conversation with Dr. Quyen Chu

ASCO Education Podcast

Cancer Topics – Beyond Adjuvant Chemotherapy: Precision Oncology in Early-stage NSCLC

ASCO Education Podcast

The podcast ASCO Education Podcast has been added to your home screen.

Dr. Jonathan Strosberg, section chief of the Neuroendocrine Tumor Division of the Moffitt Cancer Center, discusses the recent FDA approval of Lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Subscribe Install Share
ASCO Education Podcast

Thank you for your subscription

For a better experience, also consider installing the application.

Install